Montreal
Canada
McGill University - Meakins-Christie Laboratories
high-risk COVID-19, high-risk populations, severe outcomes, COVID-19, mortality, hospitalization, respirology, immunology, cardiovascular disease, nephrology, neurology, endocrinology, preventative management, therapeutic management, COVID-19 risk factors
COVID-19, mRNA Vaccination, Vaccine response, Humoral immunity, Vaccine dosing intervals
COVID-19, SARS-CoV-2, mRNA-1273, BNT162b2, antibody responses, frail elderly